Actively Recruiting
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
Led by Shanghai Institute Of Biological Products · Updated on 2026-01-08
160
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the safety, tolerability of SIBP-A10 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
CONDITIONS
Official Title
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign informed consent
- Age between 18 and 75 years, any gender
- Diagnosed with advanced tumors as specified in the study
- Have at least one measurable tumor lesion
- Able to provide tumor tissue samples or undergo tumor biopsy during screening
- Have not previously received medication targeting Siglec-15
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 1
- Expected survival of at least 3 months
- Normal main organ functions during screening
- Women of childbearing age must have a negative pregnancy test
- Subjects of reproductive age must agree to effective contraception during the study and for 6 months after last dose
You will not qualify if you...
- History of other malignant tumors not healed within past 5 years
- Presence of meningeal metastases
- Presence of active brain metastases
- History of anti-tumor treatment or surgery not complying with protocol
- Medical history or lab results not meeting protocol requirements
- Severe, progressive, or uncontrolled non-tumor diseases increasing risk
- Concomitant diseases seriously endangering safety or study completion
- Uncontrollable ascites, pleural or pericardial effusion, or recent serosal drainage
- Not recovered to grade 1 or less from prior treatment toxicities before starting
- History of severe allergies to protein products or components of study drug
- Pregnant or breastfeeding women
- Any other reasons deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital Affiliated to Dalian University
Dalian, Liaoning, China
Actively Recruiting
Research Team
D
Dan dan Chen, Master
CONTACT
B
Bao Yuan Shang, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here